{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:14:44Z","timestamp":1793499284116,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007613","name":"Ankara University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007613","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Acromegaly is most commonly caused by pituitary somatotroph adenomas, a substantial proportion of which exhibit prolactin (PRL) expression on immunohistochemistry. However, the clinical relevance and prognostic implications of this pathological phenotype remain controversial. We aimed to compare pathological features and treatment outcomes of growth hormone\/prolactin (GH\/PRL)\u2013positive adenomas with GH-only adenomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 90 patients with acromegaly who underwent transsphenoidal surgery between 2010 and 2025. Adenomas were classified according to immunohistochemical staining as GH-only, GH\/PRL, or other subtypes. Clinical, biochemical, radiological, and treatment outcomes were compared across groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 90 adenomas, 47 (52.2%) were GH-only, 39 (43.3%) GH\/PRL, and 4 (4.4%) other PIT-1 lineage adenomas. Postoperative remission was achieved in 32 patients (35.6%), with no significant difference between GH-only and GH\/PRL adenomas. In multivariable analysis, optic chiasm compression was independently associated with lower odds of remission (OR 0.212, 95% CI 0.049\u20130.910;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.037). Among 45 patients receiving SSA therapy, 25 (55.6%) achieved biochemical response. Perinuclear CK8\/18 staining (OR 4.839, 95% CI 1.198\u201319.540;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.027) and T2-weighted MRI hypointensity (OR 5.464, 95% CI 1.284\u201323.250;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.022) were independently associated with SSA response. Although Ki-67 was higher in GH\/PRL adenomas, it was not associated with treatment outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite higher proliferative activity, GH\/PRL adenomas did not demonstrate inferior surgical or medical outcomes compared with GH-only adenomas. Prognosis appears to be driven primarily by anatomical features and cytokeratin patterns, supporting individualized treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-026-01688-4","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:31:47Z","timestamp":1779085907000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hormonal staining patterns and clinical outcomes in acromegaly: a 15-year single-center study"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6969-6128","authenticated-orcid":false,"given":"Sinem Ba\u015fak Tan","family":"\u00d6ks\u00fcz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2718-3081","authenticated-orcid":false,"given":"Esra Eraslan","family":"Aydemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7807-0717","authenticated-orcid":false,"given":"Aylin Ok\u00e7u","family":"Heper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4961-6159","authenticated-orcid":false,"given":"Cevriye Cans\u0131z","family":"Ers\u00f6z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0867-6393","authenticated-orcid":false,"given":"Murat Faik","family":"Erdo\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5732-2284","authenticated-orcid":false,"given":"R\u0131fat","family":"Emral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4718-0083","authenticated-orcid":false,"given":"Mustafa","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6555-3579","authenticated-orcid":false,"given":"\u00d6zg\u00fcr","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-2960","authenticated-orcid":false,"given":"Asena G\u00f6k\u00e7ay","family":"Canpolat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0955-0717","authenticated-orcid":false,"given":"Sevim","family":"G\u00fcll\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"1","key":"1688_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L et al (2021) A Pituitary Society update to acromegaly management guidelines. Pituitary 24(1):1\u201313","journal-title":"Pituitary"},{"issue":"2","key":"1688_CR2","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s12020-019-02029-1","volume":"66","author":"L Lv","year":"2019","unstructured":"Lv L, Jiang Y, Yin S, Hu Y, Chen C, Ma W et al (2019) Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up. Endocrine 66(2):310\u20138","journal-title":"Endocrine"},{"issue":"1","key":"1688_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3171\/2018.4.JNS18230","volume":"131","author":"J Rick","year":"2019","unstructured":"Rick J, Jahangiri A, Flanigan PM, Chandra A, Kunwar S, Blevins L et al (2019) Growth hormone and prolactin-staining tumors causing acromegaly: a retrospective review of clinical presentations and surgical outcomes. J Neurosurg 131(1):147\u2013153","journal-title":"J Neurosurg"},{"issue":"2","key":"1688_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273\u2013288","journal-title":"J Clin Endocrinol Metab"},{"key":"1688_CR5","doi-asserted-by":"crossref","unstructured":"Coopmans EC, Korevaar TIM, van Meyel SWF, Daly AF, Chanson P, Brue T et al (2020) Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. J Clin Endocrinol Metab. ;105(9)","DOI":"10.1210\/clinem\/dgaa387"},{"key":"1688_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2022.101502","volume":"67","author":"ET Durmu\u015f","year":"2022","unstructured":"Durmu\u015f ET, Atmaca A, Kefeli M, \u00c7al\u0131\u015fkan S, Mete O, Aslan K et al (2022) Age, GH\/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: a clinicopathological study. Growth Horm IGF Res 67:101502","journal-title":"Growth Horm IGF Res"},{"key":"1688_CR7","doi-asserted-by":"publisher","first-page":"807054","DOI":"10.3389\/fendo.2021.807054","volume":"12","author":"X Guo","year":"2021","unstructured":"Guo X, Zhang R, Zhang D, Wang Z, Gao L, Yao Y et al (2021) Hyperprolactinemia and Hypopituitarism in Acromegaly and Effect of Pituitary Surgery: Long-Term Follow-up on 529 Patients. Front Endocrinol (Lausanne) 12:807054","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"1688_CR8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1530\/EJE-11-1119","volume":"166","author":"M Wang","year":"2012","unstructured":"Wang M, Mou C, Jiang M, Han L, Fan S, Huan C et al (2012) The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases. Eur J Endocrinol 166(5):797\u2013802","journal-title":"Eur J Endocrinol"},{"key":"1688_CR9","doi-asserted-by":"crossref","unstructured":"Araujo-Castro M, Marazuela M, Puig-Domingo M, Biagetti B (2023) Prolactin and Growth Hormone Signaling and Interlink Focused on the Mammosomatotroph Paradigm: A Comprehensive Review of the Literature. Int J Mol Sci. ;24(18)","DOI":"10.3390\/ijms241814002"},{"issue":"1","key":"1688_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C et al (2024) Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27(1):7\u201322","journal-title":"Pituitary"},{"issue":"11","key":"1688_CR11","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","volume":"21","author":"S Melmed","year":"2025","unstructured":"Melmed S, di Filippo L, Fleseriu M, Mercado M, Karavitaki N, Gurnell M et al (2025) Consensus on acromegaly therapeutic outcomes: an update. Nat Rev Endocrinol 21(11):718\u2013737","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"1688_CR12","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s11102-020-01063-x","volume":"23","author":"N Agrawal","year":"2020","unstructured":"Agrawal N, Ioachimescu AG (2020) Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review. Pituitary 23(5):582\u2013594","journal-title":"Pituitary"},{"issue":"6","key":"1688_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00428-019-02655-0","volume":"475","author":"C Villa","year":"2019","unstructured":"Villa C, Vasiljevic A, Jaffrain-Rea ML, Ansorge O, Asioli S, Barresi V et al (2019) A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. Virchows Arch 475(6):687\u2013692","journal-title":"Virchows Arch"},{"key":"#cr-split#-1688_CR14.1","unstructured":"Asa SLOR, Mete O (2025) Pituitary tumors. In: WHO Classification of Tumours Editorial Board. Endocrine and Neuroendocrine Tumours. Lyon: IARC"},{"key":"#cr-split#-1688_CR14.2","unstructured":"(WHO Classification of Tumours, 5th Edition, Vol 10). Available from: 2025 [Available from: https:\/\/tumourclassification.iarc.who.int\/chapters\/53"},{"issue":"4","key":"1688_CR15","first-page":"610","volume":"33","author":"E Knosp","year":"1993","unstructured":"Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4):610\u2013617 discussion 7\u20138","journal-title":"Neurosurgery"},{"issue":"4","key":"1688_CR16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/00004728-199207000-00004","volume":"16","author":"P Lundin","year":"1992","unstructured":"Lundin P, Pedersen F (1992) Volume of pituitary macroadenomas: assessment by MRI. J Comput Assist Tomogr 16(4):519\u2013528","journal-title":"J Comput Assist Tomogr"},{"issue":"1","key":"1688_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO classification of pituitary tumors. Endocr Pathol 33(1):6\u201326","journal-title":"Endocr Pathol"},{"issue":"1","key":"1688_CR18","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1210\/clinem\/dgae262","volume":"110","author":"LE Wildemberg","year":"2024","unstructured":"Wildemberg LE, Gadelha MR (2024) GH and prolactin co-secreting adenomas: It is time for a definition. J Clin Endocrinol Metab 110(1):e192\u2013e3","journal-title":"J Clin Endocrinol Metab"},{"key":"1688_CR19","doi-asserted-by":"publisher","first-page":"1571598","DOI":"10.3389\/fendo.2025.1571598","volume":"16","author":"L Chong","year":"2025","unstructured":"Chong L, Lou Y, Chen X, Zhao W, Zhang W, Zhang Z et al (2025) Comparison of the clinical and prognostic characteristics of patients with different pathological types in acromegaly. Front Endocrinol (Lausanne) 16:1571598","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1688_CR20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12902-021-00850-2","volume":"21","author":"M Dehghani","year":"2021","unstructured":"Dehghani M, Davoodi Z, Bidari F, Moghaddam AM, Khalili D, Bahrami-Motlagh H et al (2021) Association of different pathologic subtypes of growth hormone producing pituitary adenoma and remission in acromegaly patients: a retrospective cohort study. BMC Endocr Disord 21(1):186","journal-title":"BMC Endocr Disord"},{"issue":"12","key":"1688_CR21","doi-asserted-by":"publisher","first-page":"e2178","DOI":"10.1210\/clinem\/dgae126","volume":"109","author":"M Araujo-Castro","year":"2024","unstructured":"Araujo-Castro M, Biagetti B, Men\u00e9ndez Torre E, Novoa-Testa I, Cordido F, Pascual Corrales E et al (2024) Differences Between GH- and PRL-Cosecreting and GH-Secreting Pituitary Adenomas: a Series of 604 Cases. J Clin Endocrinol Metab 109(12):e2178\u2013e87","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1688_CR22","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol 19(12):722\u2013740","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"1688_CR23","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1055\/a-1207-1132","volume":"52","author":"D Van Laethem","year":"2020","unstructured":"Van Laethem D, Michotte A, Cools W, Velkeniers B, Unuane D, Andreescu CE et al (2020) Hyperprolactinemia in acromegaly is related to prolactin secretion by somatolactotroph tumours. Horm Metab Res 52(9):647\u201353","journal-title":"Horm Metab Res"},{"issue":"3","key":"1688_CR24","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3171\/2021.11.JNS212137","volume":"137","author":"X Guo","year":"2022","unstructured":"Guo X, Zhang R, Zhang D, Wang Z, Gao L, Yao Y et al (2022) Determinants of immediate and long-term remission after initial transsphenoidal surgery for acromegaly and outcome patterns during follow-up: a longitudinal study on 659 patients. J Neurosurg 137(3):618\u2013628","journal-title":"J Neurosurg"},{"issue":"2","key":"1688_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11060-020-03669-4","volume":"151","author":"S Yao","year":"2021","unstructured":"Yao S, Chen WL, Tavakol S, Akter F, Catalino MP, Guo X et al (2021) Predictors of postoperative biochemical remission in acromegaly. J Neurooncol 151(2):313\u201324","journal-title":"J Neurooncol"},{"issue":"11","key":"1688_CR26","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00701-016-2903-4","volume":"158","author":"D Starnoni","year":"2016","unstructured":"Starnoni D, Daniel RT, Marino L, Pitteloud N, Levivier M, Messerer M (2016) Surgical treatment of acromegaly according to the 2010 remission criteria: systematic review and meta-analysis. Acta Neurochir (Wien) 158(11):2109\u20132121","journal-title":"Acta Neurochir (Wien)"},{"issue":"6","key":"1688_CR27","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1007\/s11102-020-01075-7","volume":"23","author":"EV Varlamov","year":"2020","unstructured":"Varlamov EV, Wood MD, Netto JP, Thiessen J, Kim J, Lim DST et al (2020) Cystic appearance on magnetic resonance imaging in bihormonal growth hormone and prolactin tumors in acromegaly. Pituitary 23(6):672\u201380","journal-title":"Pituitary"},{"key":"1688_CR28","doi-asserted-by":"crossref","unstructured":"Araujo-Castro M, Biagetti B, Men\u00e9ndez E, Novoa-Testa I, Cordido F, Rodr\u00edguez Berrocal V et al (2025) Predictors of therapeutic failure in GH and prolactin co-secreting pituitary adenomas. Endocr Connect. ;14(7)","DOI":"10.1530\/EC-25-0103"},{"issue":"6","key":"1688_CR29","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s11102-023-01353-0","volume":"26","author":"HG Vuong","year":"2023","unstructured":"Vuong HG, Dunn IF (2023) Clinical and prognostic significance of granulation patterns in somatotroph adenomas\/tumors of the pituitary: a meta-analysis. Pituitary 26(6):653\u2013659","journal-title":"Pituitary"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01688-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01688-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01688-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:49:39Z","timestamp":1782409779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-026-01688-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1688"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01688-4","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ankara University Faculty of Medicine Ethics Committee (Approval Number: 2024\/37).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This work has not been previously published or presented in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior presentation"}},{"value":"Informed consent was obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}